Safety and Efficacy of Bimatoprost/Timolol (GanfortĀ®) Ophthalmic Solution in Korea
Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: bimatoprost/timolol (Drug)
Phase: N/A
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Allergan
Summary
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of
bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular
hypertension in Korea.
Clinical Details
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Number of Participants With Adverse Events and Adverse Drug Reactions
Secondary outcome: Change From Baseline in Intraocular Pressure (IOP)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients treated with GanfortĀ® for open-angle glaucoma or ocular hypertension in
clinical practice.
Exclusion Criteria:
- None.
Locations and Contacts
Seoul, Korea, Republic of
Additional Information
Starting date: August 2009
Last updated: June 22, 2015
|